Pharmaceutical development of 2-(2,7-Dichloro-9H-fluoren-4-yl)-oxirane (DBU) as a pharma-grade active ingredient is governed by the epoxide ring and the 2,7-dichloro-9H-fluorene scaffold. No public monograph exists for this specific compound; in-house specifications are therefore aligned with ICH Q6A decision trees. Particle-size distribution is measured by laser diffraction according to ISO 13320:2020, and low-dose oral solid forms require micronized API with D90 ≤20 µm to control content uniformity. Manufacturing operations follow 21 CFR 210.1 and 21 CFR 211, with component testing per 21 CFR 211.84 and batch record documentation per 21 CFR 211.188. The hydrolytic sensitivity of the oxirane ring imposes the principal process constraint: free water, alkaline pH, and nucleophilic excipients accelerate ring opening to a diol impurity. Downstream processing therefore differs materially across tablet, capsule, granule, and injectable routes.

Direct compression tablet manufacture of the low-dose oxirane API is executed as a dry process. A representative pre-lubricated blend comprises 2.0% w/w DBU, 48.5% w/w microcrystalline cellulose PH102, 48.0% w/w spray-dried mannitol, 0.5% w/w croscarmellose sodium, and 0.5% w/w colloidal silicon dioxide; magnesium stearate is added at 0.5% w/w after a 20 min bin blender mixing step at 15 rpm. The API is milled to D90 ≤20 µm before blending because low-dose solid fractions require particle-size reduction to meet content uniformity acceptance value AV ≤15 under USP <905>. Compression is performed on an instrumented rotary tablet press with pre-compression force 2–4 kN and main compression force 8–18 kN, targeting tablet hardness 80–120 N and friability not more than 1.0% after 100 drops per USP <1216>. Disintegration is controlled at ≤15 min in purified water at 37±2°C per USP <701>. The terminal product is an immediate-release oral tablet. Processing at ambient relative humidity above 60% requires pre-drying of microcrystalline cellulose and mannitol at 40–50°C to a loss on drying below 2.0%, because free moisture promotes hydrolytic ring opening of the epoxide. The main batch-to-batch failure mode observed on production equipment is segregation of micronized API during bin-to-bin transfer; this is mitigated by geometric blending with a 1:10 API-to-mannitol pre-blend for 10 min before final blending, which maintains blend uniformity RSD below 3.0% across 10 sampling points.

Roller Compaction Boundaries for a Low-Dose Oxirane Active

Roller compaction is selected when direct compression cannot accommodate poor flow or segregation of the API. The compound is pre-blended with microcrystalline cellulose PH102, crospovidone, and lactose monohydrate at a 2.0% w/w drug load. Pre-blend moisture is maintained below 2.0% by Karl Fischer titration per USP <921>. A roller compactor with side seal and vacuum deaeration is operated at roll pressure 8–12 kN/cm, roll speed 2–6 rpm, and gap 2–3 mm; the compact is milled through a 1.0 mm screen at 60–80 rpm. The tableting fraction between 180 µm and 850 µm is selected after sieve analysis. The critical process conflict occurs above 12 kN/cm, where granule hardness increases and final blend compressibility decreases due to work-hardening of the microcrystalline cellulose fraction. At roll pressure below 6 kN/cm, the compact lacks sufficient tensile strength, producing fines above 40% and reducing flow. In-process control includes bulk density and tapped density per USP <616>, with a Hausner ratio target of 1.20–1.35 and flow function coefficient ffc above 4 measured by a Jenike shear cell according to ASTM D6128-16. Final tableting is performed with extragranular croscarmellose sodium 2.0% w/w and sodium stearyl fumarate 1.0% w/w as lubricant. The terminal product is an immediate-release tablet with 10-point content uniformity RSD below 3.5% and dissolution release Q ≥80% at 30 min under USP <711> Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer. Published data for this specific compound under high roll speed remain limited; therefore the roll speed range is qualified by design of experiments using a 2³ factorial matrix rather than by fixed monograph values.

Granulation of the oxirane compound using a high-shear mixer is constrained by the hydrolytic lability of the epoxide ring. Where a granule dosage form is required, a non-aqueous binder solution of povidone K30 in anhydrous ethanol at 5.0% w/w solids is sprayed into a high-shear granulator; the dry powder charge is composed of 1.0% w/w DBU, 89.0% w/w sucrose, 5.0% w/w pregelatinized starch, 2.5% w/w sodium starch glycolate, and 1.5% w/w sodium citrate dihydrate. Impeller speed is set at 200 rpm and chopper at 1500 rpm for a total granulation time of 5–8 min. The wet mass is dried in a fluid-bed dryer with inlet air temperature 45–55°C, product temperature ≤40°C, and exhaust relative humidity below 15% until loss on drying is 0.5–1.5%. Residual ethanol is controlled below 0.5% w/w by headspace gas chromatography per USP <467>, consistent with the ICH Q3C Class 3 limit of 50 mg/day. Dried granules are milled through a 1.5 mm screen, and the fraction between 250 µm and 1000 µm is packed into sachets with fill weight variation below ±5% per Ph. Eur. 2.9.5. The terminal product is a granule for oral suspension; dispersibility is tested by adding one sachet to 100 mL water at 25±2°C, producing a suspension that passes through a 0.710 mm sieve. Because free water is excluded during manufacturing, degradation of the oxirane ring is kept below 0.10% total hydrolyzed impurity when tested by liquid chromatography against the ring-opened diol reference. Combination with amine-containing flavor systems is avoided due to potential nucleophilic ring opening at the terminal oxirane carbon.

What Limits Capsule Fill Weight Variation During High-Shear Blending?

Capsule filling of the low-dose oxirane API requires a free-flowing, cohesive powder with flow function coefficient above 4. The blend is prepared from 1.0% w/w DBU, 48.0% w/w starch 1500, 48.0% w/w lactose monohydrate, 1.0% w/w colloidal silicon dioxide, and 1.0% w/w sodium stearyl fumarate. Blending is performed in a V-blender at 25 rpm for 15 min, preceded by geometric pre-blending of the API with starch 1500 in a 1:10 ratio for 10 min to reduce segregation. Capsules are filled into hard gelatin size 3 shells using an intermittent-motion tamping pin machine with a 5-pin dosing disc and pin height 3–6 mm. Fill weight is controlled at 150 mg ±4.0%, and content uniformity is verified by weight variation and assay per USP <905>. The critical process variable is powder bed depth in the capsule filling dosing bowl; bed heights below 30 mm lead to fill weight RSD above 4.0%, while bed heights above 60 mm produce overcompression and delayed shell closure. In-process control includes capsule disintegration in 37±2°C water with a limit of ≤15 min per USP <701>. The terminal product is an immediate-release oral capsule. Dissolution testing uses USP <711> Apparatus I at 100 rpm in 900 mL of pH 1.2 or pH 6.8 medium depending on preformulation solubility. Magnesium stearate is excluded from the capsule blend because its hydrophobic coating can retard wetting; sodium stearyl fumarate is substituted at 1.0% w/w to limit dissolution lag time to ≤10 min.

When Terminal Sterilization Is Incompatible: Aseptic Filtration of the Injection Solution

Injectable manufacture of the oxirane compound is designed as an aseptic process when terminal sterilization by saturated steam at 121°C for 15 min exceeds the thermal degradation threshold of the epoxide ring. The compounded solution is prepared at 1.0–5.0 mg/mL in a buffered vehicle containing sodium chloride 0.9% w/v and citrate buffer to maintain pH 6.0–7.0. Alkaline buffers above pH 8.0 are incompatible because the oxirane ring undergoes nucleophilic ring opening by hydroxide ion; acidic conditions below pH 3.0 increase hydrolytic degradation. The solution is filtered through a 0.45 µm prefilter and then through a 0.22 µm PVDF sterilizing-grade membrane at a flux of 200–400 L/m²/h. Filter integrity is tested before and after filling by bubble point or diffusive flow according to ISO 29463-1:2017 or vendor-provided specifications. Filling is performed in an ISO Class 5 cleanroom compliant with ISO 14644-1:2015, using a rotary piston filling line with fill volume accuracy of ±2.0%. The terminal product is a sterile solution in Type I borosilicate glass vials with nitrogen overlay in the headspace; particulate matter is controlled to ≤6000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm per USP <788>. Bacterial endotoxin limits are calculated by dose-based K/M per USP <85>, not exceeding 5 EU/kg unless a lower compendial limit applies. Elemental impurities are controlled under ICH Q3D Option 1. The main production bottleneck in aseptic filtration is viscosity increase when cosolvents such as PEG 300 exceed 30% v/v; filter throughput then drops below 100 L/m²/h, and sterile filter validation by Brevundimonas diminuta challenge per ASTM F838-20 must be repeated for the final cosolvent composition.

Lyophilized vials containing the oxirane compound are prepared when solution-state hydrolysis of the epoxide ring exceeds shelf-life acceptance criteria. The pre-lyophilization solution is formulated with 10.0 mg/mL DBU, mannitol 4.0% w/v, trehalose dihydrate 2.0% w/v, and phosphate buffer pH 6.5. The solution is filtered through a 0.22 µm PVDF membrane and filled at 5 mL per 10 mL Type I glass vial. Freeze-drying is performed in a lyophilizer with shelf mapping and controlled nucleation; the freezing ramp is 0.5°C/min to -45°C with a soak of 2 h. Primary drying is conducted at shelf temperature -25°C and chamber pressure 100–150 mTorr until the product temperature rises above -30°C for at least 2 h. Secondary drying at shelf temperature 25°C for 6 h reduces residual moisture below 1.0% by Karl Fischer titration per USP <921>. The lyophilized cake is inspected for collapse, meltback, and shrinkage; collapsed cakes are rejected because reconstitution time exceeds 120 s. The terminal product is reconstituted with 5 mL water for injection to a nominal concentration of 10.0 mg/mL and must meet particulate limits per USP <788>. Published lyophilization cycle data for this specific compound are limited; collapse temperature is therefore determined by freeze-drying microscopy and electrical impedance rather than assumed from related fluorene derivatives.